| Name | Title | Contact Details |
|---|
United Medical Solutions is a Idaho Falls, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
With the help of our staff and physicians, Interior Health is proud to deliver high-quality health-care services to the communities and visitors of the Southern Interior of British Columbia. We strive to set new standards of excellence in the delivery of health services in the province of B.C. and our mission is to promote healthy lifestyles and provide needed health services in a timely, caring and efficient manner, to the highest professional and quality standards.
Pharmaceutical Technologies is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blackline Marketing specializes in helping clients in the hospitality, travel, restaurant, health care, business services, retail and food/beverage industries create integrated marketing solutions that increase revenues and maximize long-term customer engagement. Blackline Marketing helps clients in the areas of brand strategy, customer strategy, integrated marketing planning and people/process development. Clients include Northcott Hospitality/Houlihan`s restaurants, Caribou Coffee Company, HealthSource Solutions, ARC/Value Village Stores, Pebble Creek Golf Club and the MN Women`s Public Golf Association.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.